Skip to Content
UroUro
  • Review
  • Open Access

11 February 2022

10 Pages

Exploring the Role of Testosterone Replacement Therapy in Benign Prostatic Hyperplasia and Prostate Cancer: A Review of Safety

,
and
1
School of Medicine, Estácio de Sá University (UNESA), Rio de Janeiro 20261-060, RJ, Brazil
2
School of Medicine, University Center Assis Gurgacz Foundation (FAG), Cascavel 85806-095, PR, Brazil
3
School of Medicine, Federal University of Uberlandia (UFU), Uberlandia 38400-902, MG, Brazil
*
Author to whom correspondence should be addressed.

Abstract

Increased risk of prostate diseases triggered by testosterone replacement therapy (TRT) remains a worldwide concern. That said, we reviewed the safety of TRT in the spheres of benign prostatic hyperplasia (BPH) and prostate cancer (PCa), exploring clinical findings in this regard. Compelling evidence based on meta-analyses of randomized and observational studies indicates safety for TRT in patients suffering from prostate disorders such as BPH and PCa, at the same time improving lower tract urinary symptoms. Thus, the harmful relationship geared toward androgens and BPH seems to be overestimated as TRT has sufficient safety and, if properly prescribed, may counteract several metabolic problems. Even after PCa treatment, the benefits of TRT could outweigh the risk of recurrence, but further long-term randomized clinical trials are needed to elucidate unresolved questions.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.